Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:43:41.104Z.
Calculation as of: 2026-10-06T22:43:41.104Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3426d5a31c39f39b03255f489736213a5d3ef01d64930d1418f7917ed6abe5c1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$996.65M
EV/Sales Ratio
2.51x
TTM Avg
4.19x
3Y Avg
12.20x
5Y Avg
19.04x
Market Cap
$998.69M
EV/Sales Ratio
N/A
TTM Avg
38.08x
3Y Avg
38.08x
5Y Avg
38.08x
Market Cap
$982.46M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
EV/Sales Ratio
2.39x
TTM Avg
16.24x
3Y Avg
25.95x
5Y Avg
23.23x
Market Cap
$978.09M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
EV/Sales Ratio
1.58x
TTM Avg
1.77x
3Y Avg
2.17x
5Y Avg
3.33x
Market Cap
$1.02B
EV/Sales Ratio
2.78x
TTM Avg
2.39x
3Y Avg
2.22x
5Y Avg
3.30x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vor Biopharma Inc. (VOR) | $992.14M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 2.51x | 4.19x | 12.20x | 19.04x |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | N/A | 38.08x | 38.08x | 38.08x |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 2.39x | 16.24x | 25.95x | 23.23x |
| Immatics N.V. (IMTX)vs › | $1.01B | 15.60x | 15.40x | 10.40x | 9.15x |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 1.58x | 1.77x | 2.17x | 3.33x |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | 2.78x | 2.39x | 2.22x | 3.30x |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 31.91x | 409.08x | 413.14x | 302.30x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
